OMIDRIA Special Ep. 1 An OMIDRIA Overview


Dr Arjan Hura  (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

Dr Gary Foster (guest)

Dr Gary Foster is a board-certified ophthalmologist, specializing in cataract and laser eye surgery in Colorado and Wyoming.

Dr Rebecca Metzinger (guest)

Dr Rebecca Metzingeris chief of ophthalmology at the Southeast Louisiana Veterans Health Care System. Dr. Metzinger’s research interests include prevention of corneal transplant rejection, facial nerve regeneration, and immunosuppressants.

Dr Denise Visco (guest)

Dr Denise Visco is an ophthalmologist in York, Pennsylvania and is affiliated with UPMC Memorial. Dr. Visco is a pioneer of surgical advancement being the first female surgeon in the world to perform cataract surgery with the LENSAR Advanced Laser Cataract System. She is also the first in the area to offer all laser LASIK procedures and customized options for cataract surgery.

Dr Neda Nikpoor (guest)

Dr Neda Nikpoor is a fellowship-trained and board-certified ophthalmologist performing cataract, cornea, and LASIK surgery at Aloha Laser Vision. As a highly acclaimed ophthalmologist, Dr. Nikpoor has made a positive global impact during her career.

Dr Inder Paul Singh (guest)

Dr Inder Paul Singh is an ophthalmologist in Racine, Wisconsin and is President of The Eye Centers of Racine & Kenosha, Ltd. He has a strong passion for new technology. He was the first surgeon in Wisconsin to perform many of the minimally invasive glaucoma surgeries (MIGS), such as the iStent, Cypass, Hydrus, and Kahook Dual Blade goniotomy. In 2021, Newsweek named Dr. Singh America’s Best Eye Doctor for quality of care, continuity of care, and the quality of the technology used in his practice.

Dr Kendall Donaldson (guest)

Dr Kendall Donaldson is a cornea specialist at the Bascom Palmer Eye Institute, whose primary research interests are in the areas of advancement in cataract surgery, and in particular, laser-assisted cataract surgery, and severe ocular surface disease. She performs various types of corneal transplantation procedures, laser vision correction procedures, ocular surface reconstruction, and cataract surgery.

Dr Keith Walter (guest)

Dr Keith Walter is a Professor of Ophthalmology, Director of the Cornea Fellowship and also a LASIK eye surgeon with Wake Forest Baptist Health in Winston-Salem, NC.

Mitch Jackson (guest)

Mitch Jackson is a board-certified ophthalmologist specializing in cataract and refractive surgery. He is the Founder and Medical Director of Jackson Eye and is also a clinical associate at the University of Chicago Hospitals.



This episode of ‘Peer2Peer: The Podcast’ is the first from a series of four episodes dedicated to OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. Dr Arjan Hura, together with top surgeons Gary Foster, Rebecca Metzinger, Denise Visco, Neda Nikpoor, Inder Paul Singh, Kendall Donaldson, Keith Walter, Mitch Jackson share their thoughts and experience on the use of OMIDRIA in cataract surgery. They highlight the benefits of incorporating OMIDRIA, including an improved surgeon, practice, and patient perioperative experience.


Key Takeaways:

  • Incorporating OMIDRIA can enhance safety and predictability in the surgical practice.
  • Integrating OMIDRIA into cataract surgery training programs may ease the procedure for new surgeons, reduce complications, and enhance surgical outcomes. The experiences shared by surgeons highlight the efficacy, safety, and positive impact of OMIDRIA in cataract surgery.
  • Surgeons recommend contacting OMIDRIA representatives when starting to use the product, as Field Reimbursement Managers can assist with billing and reimbursement questions and Sales Representatives can help provide guidance on integration into the surgical workflow. Many surgeons have been pleased with the new enhanced OMIDRIAssure Patient Access Program. 

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.



OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.


Additional Resources:

Peer2Peer educational platform:


US-OM-2300030 07/23


OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.


OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit, or call 1-800-FDA-1088.

This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.

Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2023 Rayner Group, all rights reserved. US-OM-2200071v4 11/23